ATE461275T1 - Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität - Google Patents

Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität

Info

Publication number
ATE461275T1
ATE461275T1 AT03749716T AT03749716T ATE461275T1 AT E461275 T1 ATE461275 T1 AT E461275T1 AT 03749716 T AT03749716 T AT 03749716T AT 03749716 T AT03749716 T AT 03749716T AT E461275 T1 ATE461275 T1 AT E461275T1
Authority
AT
Austria
Prior art keywords
myostatin
metalloprotease
activation
agent
decreasing
Prior art date
Application number
AT03749716T
Other languages
English (en)
Inventor
Se-Jin Lee
Alexandra Mcpherron
Daniel Greenspan
William Pappano
Neil Wolfman
Kathy Tomkinson
Original Assignee
Univ Johns Hopkins
Wisconsin Alumni Res Found
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Wisconsin Alumni Res Found, Wyeth Corp filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE461275T1 publication Critical patent/ATE461275T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03749716T 2002-09-16 2003-09-16 Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität ATE461275T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41113302P 2002-09-16 2002-09-16
US43916403P 2003-01-09 2003-01-09
US48686303P 2003-07-10 2003-07-10
PCT/US2003/029079 WO2004024890A2 (en) 2002-09-16 2003-09-16 Metalloprotease activation of myostatin, and methods of modulating myostatin activity

Publications (1)

Publication Number Publication Date
ATE461275T1 true ATE461275T1 (de) 2010-04-15

Family

ID=31999236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03749716T ATE461275T1 (de) 2002-09-16 2003-09-16 Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität

Country Status (12)

Country Link
US (3) US7572599B2 (de)
EP (3) EP2192129A1 (de)
JP (3) JP2006507356A (de)
AT (1) ATE461275T1 (de)
AU (3) AU2003267246A1 (de)
BR (2) BR0314380A (de)
CA (2) CA2498044A1 (de)
DE (1) DE60331778D1 (de)
ES (1) ES2344734T3 (de)
IL (1) IL166651A (de)
MX (2) MXPA05002968A (de)
WO (2) WO2004024890A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572909A4 (de) * 2002-02-21 2007-06-06 Wyeth Corp Protein mit follistatindomäne
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
EP1799709B1 (de) * 2004-09-30 2012-04-04 ORICO Limited Myostatin-isoform
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
EP1864138A2 (de) * 2005-03-23 2007-12-12 Wyeth Erkennung von gdf-8 modulierenden wirkstoffen
EP1951756B1 (de) * 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin-antikörper
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP1880731A1 (de) * 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Menschlicher Wachstums und Differenzierungsfaktor GDF-5
AU2012200193B2 (en) * 2006-07-21 2015-04-09 Genera Istrazivanja D.O.O. BMP-1 procollagen C-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
JP5016041B2 (ja) 2006-07-21 2012-09-05 ゲネラ・イストラジヴァンジャ・ディーオーオー 骨および軟組織欠損および障害の診断および処置のためのｂｍｐ−１プロコラーゲンｃ−プロテイナーゼ
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
ES2358028B1 (es) * 2009-10-19 2011-11-28 Universidade De Santiago De Compostela Procedimiento de obtención de catalizadores híbridos compuestos por complejos de metales de transición encapsulados en nanopartículas porosas de sílice, titania o circonia.
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
EP2986158A1 (de) 2013-03-15 2016-02-24 Abbott Laboratories Verfahren zur bewahrung und verbesserung der muskelfunktion
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
BR112016016130A2 (pt) 2014-01-10 2017-08-08 Glaxosmithkline Ip No 2 Ltd Compostos e métodos
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
EP3215175A4 (de) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latentes-myostatin-antikörper und verwendungen davon
KR101860280B1 (ko) * 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
WO2017075037A1 (en) * 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
EP3494991A4 (de) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
EP4218817A3 (de) 2017-01-06 2023-09-06 Scholar Rock, Inc. Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2021060884A1 (ko) * 2019-09-24 2021-04-01 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
EP4638496A1 (de) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selektive und potente hemmende antikörper der myostatinaktivierung

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591227B1 (fr) * 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
EP1716864A1 (de) * 1993-08-26 2006-11-02 Genetics Institute, LLC Neuronale Regeneration mit menschlichen morphogenischen Knochenproteinen
EP1574577A3 (de) * 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Wachstums-Differenzierungsfaktor-11
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP1572909A4 (de) * 2002-02-21 2007-06-06 Wyeth Corp Protein mit follistatindomäne
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
JP2005042091A (ja) * 2003-07-04 2005-02-17 Nitto Denko Corp 電気絶縁材料用ポリイミド樹脂

Also Published As

Publication number Publication date
US20040138118A1 (en) 2004-07-15
AU2010201977A1 (en) 2010-06-03
US20060275280A1 (en) 2006-12-07
IL166651A (en) 2013-12-31
BR0314380A (pt) 2005-07-19
JP2006507356A (ja) 2006-03-02
JP5369044B2 (ja) 2013-12-18
CA2496213C (en) 2013-11-19
MXPA05002648A (es) 2005-08-19
BR0314270A (pt) 2005-08-02
EP1549747A4 (de) 2006-08-23
JP2010248195A (ja) 2010-11-04
EP1578928A2 (de) 2005-09-28
JP4547561B2 (ja) 2010-09-22
WO2004024890A2 (en) 2004-03-25
MXPA05002968A (es) 2005-09-08
EP2192129A1 (de) 2010-06-02
EP1549747A2 (de) 2005-07-06
US20050043232A1 (en) 2005-02-24
WO2004024092A2 (en) 2004-03-25
IL166651A0 (en) 2006-01-15
EP1578928B1 (de) 2010-03-17
WO2004024092A3 (en) 2004-08-26
WO2004024890A3 (en) 2006-07-27
EP1578928A4 (de) 2007-01-03
CA2496213A1 (en) 2004-03-25
JP2006517525A (ja) 2006-07-27
AU2003267246A1 (en) 2004-04-30
ES2344734T3 (es) 2010-09-06
AU2003272394A1 (en) 2004-04-30
DE60331778D1 (de) 2010-04-29
US7572599B2 (en) 2009-08-11
CA2498044A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE461275T1 (de) Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
DE60035163D1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
DE69817211D1 (de) Charakterisierung von polypeptiden
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
DE60034248D1 (de) Methode zur erzeugung von daten für bauteilbestückungseinrichtung, bestückungsmethode und einrichtungen dafür
DE69833699D1 (de) Gefässverschliessende Vorrichtung zur Behandlung von Aneurismen
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
ATE324106T1 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
DE69834828D1 (de) Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
WO2003104282A8 (en) Glycoprotein vi - fc fusion protein for treating vascular disorders
ES2079481T3 (es) Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE69938451D1 (de) Fas peptide und antikörper zur modulierung von apoptosis
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
HUP0301795A2 (hu) Emberi D-G szerinproteázt kódoló DNS
ATE185146T1 (de) Verfahren zur entfernung von n-terminalem methionin
DE69831500T2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE60238449D1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
DE60140493D1 (de) Verfahren zur Reinigung stark anionischer Proteine
DE19881185D2 (de) Vorrichtung zur Zerstörung bzw. Zertrümmerung von Konkrementen
ATE416260T1 (de) Verfahren zur überwachung und modulierung von proteinfaltung
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
DE59812449D1 (de) Vorrichtung zur laserablation von gewebe
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties